Literature DB >> 18451130

Oncogene addiction.

I Bernard Weinstein1, Andrew Joe.   

Abstract

Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called "oncogene addiction," provides a rationale for molecular targeted therapy. The efficacy of this strategy requires novel methods, including integrative genomics and systems biology, to identify the state of oncogene addiction (i.e., the "Achilles heel") in specific cancers. Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction.

Entities:  

Mesh:

Year:  2008        PMID: 18451130     DOI: 10.1158/0008-5472.CAN-07-3293

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  355 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  Targeting MYC dependence in cancer by inhibiting BET bromodomains.

Authors:  Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex.

Authors:  Robert V Brown; Forest L Danford; Vijay Gokhale; Laurence H Hurley; Tracy A Brooks
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

4.  Transcriptional output in a prospective design conditionally on follow-up and exposure: the multistage model of cancer.

Authors:  Eiliv Lund; Sandra Plancade
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-10

5.  Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.

Authors:  Tiannan Guo; Yi Zhu; Chee Sian Gan; Sze Sing Lee; Jiang Zhu; Haixia Wang; Xin Li; James Christensen; Shiang Huang; Oi Lian Kon; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-08-16       Impact factor: 5.911

Review 6.  MYC as a regulator of ribosome biogenesis and protein synthesis.

Authors:  Jan van Riggelen; Alper Yetil; Dean W Felsher
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 7.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 8.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

9.  Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Authors:  Rong Chen; William G Wierda; Sherri Chubb; Rachael E Hawtin; Judith A Fox; Michael J Keating; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 10.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.